Ezetimibe as the Preferred Adjunct Lipid‑Lowering Therapy for Adults > 65 Years

Guideline Recommendations

The 2018 ACC/AHA cholesterol guideline gives a Class IIa recommendation that ezetimibe be added to maximally tolerated statin therapy when LDL‑C remains ≥70 mg/dL, noting its lower cost relative to PCSK9 inhibitors. 1
For patients ≥75 years, the ACC/AHA guideline states it is reasonable to add ezetimibe after assessing ASCVD risk reduction, adverse‑effect profile, drug interactions, frailty, and patient preferences. 2
In patients > 65 years with controlled LDL‑C and total cholesterol on moderate‑to‑high‑intensity statins, ezetimibe is recommended as the preferred adjunct over fenofibrate because of demonstrated cardiovascular outcome benefit and a superior safety profile in this age group. 1

The IMPROVE‑IT randomized trial showed that adding ezetimibe to simvastatin reduced major cardiovascular events by 17 % overall, by 21 % in participants without established CVD, and by 22 % in those not receiving dialysis. (Level A evidence) 4
In the ACCORD‑Lipid trial, fenofibrate added to simvastatin did not lower cardiovascular events in adults with diabetes (aged 40‑79) compared with simvastatin alone, indicating no incremental benefit. (Level A evidence) 5

Combination therapy with ezetimibe and a statin produced only a modest rise in muscle‑related symptoms requiring discontinuation (1.1 % vs 0.6 %; p = 0.02) and did not increase rates of elevated liver enzymes, cancer, hemorrhagic stroke, or non‑cardiovascular mortality. (Level A evidence) 4
Fenofibrate, when combined with statins, is associated with higher incidences of pancreatitis, pulmonary embolism, and a mean creatinine increase of ~0.12 mg/dL; it also raises the risk of statin‑related myopathy, especially when used with gemfibrozil. (Level A evidence) 6

The 2013 ACC/AHA guideline notes that fenofibrate modestly reduced CHD/CVD events only in diabetic patients without clinical ASCVD (primary prevention) and provided no benefit in secondary‑prevention populations. 5
Fenofibrate may be considered only for patients with markedly elevated triglycerides (≥204 mg/dL) and low HDL‑C (≤40 mg/dL), a subgroup in which post‑hoc analyses suggested some benefit; this scenario is unlikely when LDL‑C and total cholesterol are already at target. 5

LDL‑C ≥ 70 mg/dL despite maximally tolerated statin – add ezetimibe 10 mg daily. (Class IIa, ACC/AHA) 1
Elevated triglycerides (≥150 mg/dL) with low HDL‑C – first intensify lifestyle measures; if triglycerides remain ≥204 mg/dL and HDL‑C ≤40 mg/dL, fenofibrate can be considered, but ezetimibe remains the preferred agent for overall ASCVD risk reduction. (Level B) 7
Monitoring – obtain a lipid panel 4–12 weeks after initiating ezetimibe to assess response. (Level C) 8
Patients ≥ 75 years – evaluate frailty, drug‑drug interactions, and life expectancy before any therapy intensification; ezetimibe is favored as the safest option for additional LDL‑C lowering. (Class IIa) 2

Ezetimibe has minimal cytochrome‑P450–mediated interactions, making it safer than fenofibrate, which interacts significantly via CYP pathways and heightens myopathy risk when combined with statins. (Level B) 6